Corvaltab (20 tablets)
One tablet contains active ingredients:
- ethyl ester of α-bromoisovaleric acid – 8.2 mg
- phenobarbital – 7.5 mg
- mint oil – 0.58 mg
Excipients: β-cyclodextrin, potato starch, tabletose (lactose monohydrate), microcrystalline cellulose, magnesium stearate.
Phenobarbital is well absorbed from the gastrointestinal tract. The distribution of phenobarbital is slower than that of other barbiturates due to the lowest lipophilicity. Partially binds to plasma proteins (mainly albumin). Metabolized in the liver with the participation of microsomal enzymes by hydroxylation. The half-life (T 1/2) in adults is 2-4 days. With repeated use, material cumulation is characteristic. Continuous long-term use of barbiturates leads to the development of addiction. Excreted by the kidneys.
Peppermint oil is rapidly absorbed from the gastrointestinal tract. The main component of peppermint oil – menthol is transformed in the liver to form a conjugate with glucuronic acid, which is excreted from the body through the kidneys.
The ethyl ester of α-bromoisovaleric acid is metabolized by deesterification to form isovaleric acid.
Corvaltab helps to reduce the excitability of the central nervous system, has a calming effect and facilitates the onset of natural sleep. The ethyl ester of a-bromoisovaleric acid, which is part of the preparation, has a sedative and antispasmodic effect, similar to the action of valerian extract; in large doses, it also has a mild hypnotic effect. Phenobarbital has a vasodilating and sedative effect, hypnotic in appropriate doses. Peppermint oil has reflex vasodilating and antispasmodic effects.
Indications for use
– neurosis with increased irritability
– increased excitability
– insomnia, including insomnia
– neurocircular dystonia (including tachycardia, spasm of the coronary vessels)
– arterial hypertension of the 1st degree
– spasms of the digestive tract, caused by neurovegetative disorders
Method of application and dosage
The drug is taken orally. The dosage and duration of the course of treatment are set by the doctor individually for each patient. Adults are usually prescribed 1-2 tablets of the drug 2-3 times a day before meals. With tachycardia and spasms of the coronary vessels, a single dose can be increased to 3 tablets.
– daytime sleepiness
– skin allergic reactions that disappear when the dose is reduced or the drug is stopped
– hypersensitivity to the components of the drug
– severe impairment of kidney and liver function
– hepatic porphyria
– pregnancy and lactation period
When taken simultaneously with sedatives – increased effect of the drug.
The drug can increase the toxicity of methotrexate.
Simultaneous use with neuroleptics and anxiolytics – enhances, and with stimulants of the central nervous system – weakens the effect of the drug.
Ethanol (alcohol) enhances the effects of the drug and may increase its toxicity. Phenobarbital reduces the antibacterial activity of antibiotics and sulfonamides, the antifungal effect of griseofulvin (reduces absorption), the effectiveness of indirect anticoagulants, HSC, doxycycline, estrogens metabolized in the liver along the oxidation pathway (accelerates their destruction).
The drug contains lactose, so Corvaltab is not recommended for patients with hereditary lactose-galactose intolerance.
While taking the drug should not drink alcohol.
Application in pediatrics
There is no experience in the treatment of children, so the drug is not used in pediatric practice.
Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms
During treatment with the drug, it is not recommended to engage in activities that require increased attention, rapid mental and motor reactions.
Symptoms: drowsiness, weakness, dizziness.
Treatment: discontinuation of the drug, gastric lavage and symptomatic therapy.
There is no specific antidote.
Store in original packaging, at a temperature not exceeding 25 ºС.
Keep out of the reach of children!
Shelf life – 2 years
Do not use after the expiration date
There are no reviews yet.